格理集團
成立一年
1998年階段
私人股本——二世 |活著總了
692美元估值
0000美元最後提出了
212美元 | 7年前收入
0000美元缺失:格理集團的產品演示和案例研究
促進你的產品提供技術買家。
達到1000年代的買家使用CB的見解來確定供應商,演示產品,188bet游戏做出購買決定。
缺失:格理集團的產品&微分器
不要讓你的產品被跳過。買家使用我們的供應商排名名單公司和驅動(rfp)請求建議。
研究包含格理集團
獲得CB的數據驅動的專家分析見解信息部。188bet游戏
188bet游戏CB見解情報分析家提到格理集團3 188bet游戏CB見解研究簡報,最近在2021年12月1日。
2021年12月1日
專家網絡GLG泰加了90美元,第三大橋,Guidepoint, AlphaSights2021年8月31日
專家網絡服務提供商圖書館提高股權融資151美元的增長2020年10月8日
殺死策略:管理谘詢的中斷格理集團專利
格理集團已申請專利。
申請日 |
授予日期 |
標題 |
相關的話題 |
狀態 |
---|---|---|---|---|
7/24/2012 |
12/31/2013 |
|
格蘭特 |
申請日 |
7/24/2012 |
---|---|
授予日期 |
12/31/2013 |
標題 |
|
相關的話題 |
|
狀態 |
格蘭特 |
最新的格理集團新聞
2022年10月17日
披露:奧地利聯邦數字和經濟事務部;基督教多普勒研究協會;維也納醫科大學;國家基礎研究、技術和發展;和Sudtiroler Sanitatsbetriebt支持這項研究。Preusser報告個人費用從AbbVie Adastra,阿斯利康,拜耳,BMJ雜誌,百時美施貴寶公司,CMC之下,第一三共製藥,禮來,Gan & Lee製藥、格理集團,葛蘭素史克,Medahead, MedMedia,默克公司大幅& Dohme Mundipharma,諾華,羅氏公司,賽諾菲和Tocagen外提交的工作。請參閱研究對於所有其他作者的相關財務信息披露。主題添加到郵件提醒收到一封電子郵件在發布新文章時請提供您的電子郵件地址來接收電子郵件當張貼新文章。請稍後再試。如果你繼續這個問題請聯係customerservice@slackinc.com。 Back to Healio A fourth dose of the COVID-19 vaccine increased humoral immunity among patients with solid and hematologic cancers, according to study results published in JAMA Oncology. However, passive immunization with the long-acting monoclonal antibodies tixagevimab and cilgavimab (Evusheld; AstraZeneca) did not appear effective against omicron sublineages BA.1 and BA.4, researchers noted. “We recommend a fourth COVID-19 vaccine dose to our patients with solid and hematologic cancers, based on our findings,” researcher Matthias Preusser, MD, told Healio. Source: Adobe Stock Background and methods “We and other groups showed earlier this year that a third vaccination dose increased humoral immunity against COVID-19 in patients with cancer ,” Matthias Preusser, MD, professor of medical oncology and head of the clinical division of oncology at Medical University of Vienna, told Healio. “However, new virus variants of concern keep emerging and are a particular threat to immunocompromised patients, such as those with cancer. We therefore sought to investigate whether a fourth vaccine dose, or antibody-based preexposure prophylaxis, was capable of increasing the immunity in this patient population.” Matthias Preusser Preusser and colleagues compared antibody levels against the receptor-binding domain of the spike protein of COVID-19 hu-1 and omicron sublineages BA.1 or BA.4 among 72 patients (median age, 74 years; 65.3% men) with cancer who received a fourth dose of COVID-19 vaccination (n = 54) or tixagevimab and cilgavimab (n = 18). Most of those who received the fourth vaccination (n = 33) had hematologic malignant neoplasms, whereas 21 had solid tumors. Investigators also assessed the inhibition of the interaction between receptor-binding domains and the receptor angiotensin-converting enzyme 2. Findings Results showed median anti-receptor-binding domains increased from before to after fourth vaccination against omicron sublineages BA.1 (0.154 optical density to 0.969 optical density; P = .02) and BA.4 (0.245 to 0.966; P = .02) among patients with hematologic malignant neoplasms undergoing B cell–targeted therapy. Of note, researchers observed no other differences in antibody levels among those with other hematologic diseases. Among those with solid malignant neoplasms, researchers identified pronounced increases in median anti-receptor-binding domains before vs. after the fourth vaccination dose against variants hu-1 (1.157 optical density vs. 1.438 optical density; P = .02), BA.1 (0.721 vs. 1.026; P = .003) and BA.4 (0.556 vs. 1.22; P = .002). Moreover, the potential inhibition of the interaction between receptor-binding domains and the receptor angiotensin-converting enzyme 2 appeared higher after the fourth vaccination dose among patients with hematologic disease and solid tumor cancers, especially for sublineages BA.1 and BA.4, according to the researchers. Researchers further observed median inhibition of receptor-binding domains and the receptor angiotensin-converting enzyme 2 with tixagevimab and cilgavimab of 99.9% for sublineage hu-1, 34.9% for BA.1 and 15.4% for BA.4. “We recommend a fourth COVID-19 vaccine dose to our patients with solid and hematologic cancers, based on our findings,” Preusser said. “However, we discourage passive immunization with tixagevimab and cilgavimab, because we saw very limited blocking activity against currently circulating COVID-19 variants.” Future research Next steps include the examination of the cellular immune response to the fourth vaccination dose to obtain a better understanding of the potential memory effects on the immune system, Preusser said. “In addition, we are planning studies on long-COVID-19 and humoral immune responses to adapted vaccines and a fifth vaccination dose, which is also already being considered in immunocompromised individuals,” he added. For more information
格理集團網絡流量
格理集團排名
格理集團常見問題(FAQ)
格理集團成立是什麼時候?
格理集團成立於1998年。
格理集團的總部在哪裏?
格理集團的總部位於60東第42街,紐約。
格理集團的最新一輪融資是什麼?
格理集團的最新一輪融資是私人股本- II。
格理集團籌集了多少錢?
格理集團籌集了總計692美元。
格理集團的投資者是誰?
格理集團的投資者包括矽穀銀行SFW Capital Partners銀湖、酸性Venture Partners和普林斯頓的企業。
格理集團的競爭對手是誰?
格理集團的競爭對手包括泰加,techspert。密封的網絡io, Arbolus MDisrupt,詢問AI, Inex, Lynk,藝術學院,科爾曼研究集團和13。
比較格理集團的競爭對手
答:是一個在線學習平台,提供專業的機構投資者獲得全球行業專家包括工作流從提交給SEC的備案文件表麵和分析數據,以及專家訪談服務。它提供用戶探索新的可行的投資理念,同行的提問,並與專家接觸。它迎合全球範圍廣泛的客戶,包括投資公司,公司和谘詢公司。公司成立於2017年,總部設在芝加哥,伊利諾斯州。
AlphaSights已成為首選的知識夥伴最大的谘詢公司,私人股本基金,投資銀行和企業,幫助他們獲得他們所需要的知識更好地,更明智的投資決策。
第三大橋提供了私人股本公司、對衝基金、和戰略谘詢公司提供專家通過他們的專家網絡。公司的產品提供了一個論壇訂閱電話記錄由球隊與專家在各空間。
proSapient是一個機器學習的研究平台,幫助合作夥伴在全球進行主要研究。
密封是一個專家網絡完全集中在東南亞。他們連接局部主題工業專業人士對企業要求的見解。
Lynk是一個商業建議平台專用連接人們的專家建議,洞察力,和公司的AI-driven知識管理平台可以有效的訪問在規模專業技能和知識,尋求創建一個平台,構建和分享可信的人類經驗。其產品,答案和圓,給企業快速,方便,和成本效益的方式來組織、連接和與個人相關的專業知識和經驗。Lynk成立於2015年,總部設在紐約,紐約。
發現正確的解決方案為您的團隊
CB見解188bet游戏科技市場情報平台分析數百萬數據點在供應商、產品、合作關係,專利來幫助您的團隊發現他們的下一個技術解決方案。